scholarly journals Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial

2017 ◽  
Vol 19 (5) ◽  
pp. 754-758 ◽  
Author(s):  
Linong Ji ◽  
Ling Li ◽  
Jian Kuang ◽  
Tao Yang ◽  
Dong-Jun Kim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Asian Patients ◽  
Dose Combination

Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus

2014 ◽  
Vol 20 (12) ◽  
pp. 1322-1332 ◽  
Author(s):  
Lawrence Blonde ◽  
Zinnia T. San Juan ◽  
Peggy Bolton
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

scholarly journals Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin

2019 ◽  
pp. 138-145
Author(s):  
N. A. Petunina ◽  
A. L. Terekhova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination ◽  
Early Combination Therapy

 This paper discusses the possibilities and benefits of early combination therapy and the application features of a fixed-dose combination of metformin and alogliptin (Vipdomet®) in the treatment of type 2 diabetes mellitus (DM 2).

Sign in / Sign up

Export Citation Format

Share Document